Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Alpha Compute Corp

Ticker
ALP
Sector
Industry
Report date
July 16, 2026
Valye AI Score

90

Very high visibility
Recent developments
Recent developments summary

Recent news coverage primarily relates to AlphaTON Capital and Portage Biotech, which are distinct entities from Alpha Compute Corp. No direct recent business developments for Alpha Compute Corp were reported in the news.

Recent developments:
  • HC Wainwright & Co. initiated coverage of AlphaTON Capital (ATON) with a buy recommendation in February 2026 [N1].
  • AlphaTON Capital appointed Wes Levitt as new CFO in October 2025 [N2].
  • Portage Biotech regained Nasdaq compliance and maintained listing on the capital market in June 2025 [N3].
  • Portage Biotech entered a subscription agreement with Compedica Holdings Limited for a strategic equity investment in June 2025 [N4].
  • Portage Biotech resumed patient enrollment in the final cohort of dose escalation stage for PORT-6 clinical trial in March 2025 [N6][N7][N8].
Overview

Alpha Compute Corp is a company with limited publicly available information regarding its sector, industry, and country of operation. The most recent comprehensive financial data dates back to fiscal year 2018, indicating strong liquidity and profitability at that time. The company engaged in an equity investment in Compedica Ltd., a UK biotechnology firm, in 2025 but subsequently lost significant influence and exited the investment by early 2026. The company has contingent put options related to a 2025 private placement financing, obligating it to repurchase shares and warrants with settlement in TON tokens and USDC stablecoins. The company also entered into a GPU equipment lease in late 2025, with a disputed purchase option. Recent news items do not provide direct information about Alpha Compute Corp's current business activities or financial performance.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Alpha Compute Corp's latest detailed financial data is from fiscal year ended March 31, 2018, showing strong liquidity and a net income of $123.7 million. Recent SEC filings disclose the company's investment in Compedica Ltd. and related losses, as well as contingent put options from a 2025 private placement financing with obligations settled in digital assets. Recent news coverage primarily relates to other entities and does not provide direct updates on Alpha Compute Corp's business operations.

Scenarios for ALP

Bull case model:

Not applicable due to limited visibility and lack of detailed business model and operational disclosures.

Bear case model:

Not applicable due to limited visibility and lack of detailed business model and operational disclosures.

Moat:

Due to limited disclosure, there is insufficient information to assess Alpha Compute Corp's competitive advantages or moat. The company's investment in a biotechnology firm and involvement in digital asset treasury activities suggest diversification, but the lack of detailed operational data precludes a clear evaluation of sustainable competitive strengths.

Risks overview
Risks summary
The primary risks stem from investment losses, contingent repurchase obligations settled in volatile digital assets, and limited transparency on the company's ongoing operations and business model.
Risks details:

• Investment and Market Risk: The company recorded significant impairment losses related to its investment in Compedica Ltd., indicating exposure to investment risk in pre-revenue biotechnology ventures.
• Liquidity and Settlement Obligations: The contingent put options obligate the company to repurchase shares and warrants with settlement in digital assets and stablecoins, creating potential liquidity and valuation risks given the volatility of such assets.
• Operational Uncertainty: Limited disclosure on current operations, sector, and industry creates uncertainty about the company's business model, revenue sources, and sustainability.
• Disputed Asset Acquisition: The GPU equipment lease purchase option was disputed, indicating potential operational or contractual risks in asset acquisitions.

FINAL FORECAST FOR ALP

Final take one line
Alpha Compute Corp exhibits low visibility with limited recent financial and operational disclosures, notable investment activities, and contingent repurchase obligations settled in digital assets.
Final take 12 to 24 month view

Business trends: The company has transitioned towards digital asset treasury activities and investment in biotechnology, with significant involvement in contingent put options and digital asset settlements.
Execution milestones: Completion of private placement financing in September 2025, acquisition and exit of investment in Compedica Ltd., and management of contingent put options and related settlements through early 2026.
Key risks: Exposure to investment impairments, liquidity and valuation risks from contingent repurchase obligations in volatile digital assets, operational uncertainties due to limited disclosure, and contractual disputes in asset acquisitions.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

90
LLM visibility overview
LLM Visibility known facts
  • Alpha Compute Corp is a company with limited public disclosure on its sector, industry, and country of operation as of July 16, 2026.
  • The latest available financial snapshot is from fiscal year ended March 31, 2018, showing cash and equivalents of $7.52 million, short-term investments of $52,000, current assets of $7.62 million, and current liabilities of $127,000, resulting in a very high current ratio of 59.97 and cash ratio of 59.62, indicating strong liquidity at that time.
  • Net income for fiscal year ended March 31, 2018 was $123.7 million with basic and diluted EPS of $0.46 per share.
  • The company had an investment in Compedica Ltd., a UK-based biotechnology company, acquired in June 2025 via stock-for-stock transaction for a 6% interest valued at $5 million plus $0.1 million expenses, accounted for under equity method until September 2025 when significant influence was lost and investment was reclassified as a financial instrument under IFRS 9.
  • Alpha Compute recorded losses related to its investment in Compedica, including a $4.8 million impairment loss and a $0.2 million loss on change in fair value, and exited the investment in February 2026.
  • The company has contingent put options related to a September 2025 private placement financing, granting investors rights to require repurchase of ordinary shares and pre-funded warrants, with settlement obligations in TON tokens and USDC stablecoins.
  • As of March 31, 2026, the put right liability was valued at $7.1 million, with changes in fair value recorded as other losses.
  • Several put options were exercised in late 2025 and early 2026, resulting in losses on exercise and settlements involving TON tokens and USDC stablecoins.
  • The company entered into a GPU equipment lease in November 2025 with a purchase option exercised in February 2026, but the delivery of the GPU equipment was disputed and the company is pursuing a refund.
  • Recent news items mention AlphaTON Capital, a different entity, including coverage initiation by HC Wainwright & Co. in February 2026 and appointment of a new CFO in October 2025, which are not directly related to Alpha Compute Corp.
  • No recent financial results or operational updates for Alpha Compute Corp are publicly disclosed beyond the 2018 fiscal year and the 2025-2026 investment and put option activities disclosed in SEC filings.
Sources
Sources - Context summary

Generated 2026-07-16

Sources - Earning calls
Sources - Other context
  • S1: 20-F filing dated 2026-07-15
  • S2: 6-K filing dated 2026-07-02
Sources - SEC Filings
  • S1 | 2026-07-15 | 20-F
  • S2 | 2026-07-02 | 6-K
Sources - News headlines
  • N1 | 2026-02-24 | www.nasdaq.com | HC Wainwright & Co. Initiates Coverage of AlphaTON Capital (ATON) with Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-initiates-coverage-alphaton-capital-aton-buy-recommendation
  • N2 | 2025-10-24 | www.nasdaq.com | AlphaTON Capital Appoints Wes Levitt As New CFO | https://www.nasdaq.com/articles/alphaton-capital-appoints-wes-levitt-new-cfo
  • N3 | 2025-06-25 | www.nasdaq.com | Portage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | https://www.nasdaq.com/articles/portage-biotech-regains-nasdaq-compliance-maintains-listing-capital-market
  • N4 | 2025-06-09 | www.nasdaq.com | Portage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity Investment | https://www.nasdaq.com/articles/portage-biotech-inc-enters-subscription-agreement-compedica-holdings-limited-strategic
  • N5 | 2025-03-28 | www.nasdaq.com | PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News | https://www.nasdaq.com/articles/prtg-soars-mesothelioma-data-nvno-awaits-fda-decision-curevac-jumps-patent-news
  • N6 | 2025-03-12 | www.nasdaq.com | Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6 | https://www.nasdaq.com/articles/portage-biotech-resumes-patient-enrollment-final-cohort-dose-escalation-stage-port-6
  • N7 | 2025-03-12 | www.nasdaq.com | Portage Advances PORT-6 Clinical Trial With Encouraging Safety Data, Resumes Enrollment | https://www.nasdaq.com/articles/portage-advances-port-6-clinical-trial-encouraging-safety-data-resumes-enrollment
  • N8 | 2025-03-12 | www.nasdaq.com | Portage Biotech Resumes Patient Enrollment in Final Cohort of PORT-6 Clinical Trial | https://www.nasdaq.com/articles/portage-biotech-resumes-patient-enrollment-final-cohort-port-6-clinical-trial
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine